Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept with LAVA-051 by demonstrating efficacy and safety in a variety of preclinical models. LAVA-051 uniquely activates both Vγ9Vδ2 T cells as well as invariant natural killer T cells, which represent another conserved immune effector cell population, in a target dependent manner.
We plan to begin a Phase I/IIa clinical trial in patients with relapsed and/or refractory multiple myeloma and CLL in the first half of 2021.
LAVA-1207, a gamma-delta bsTCE targeting the prostate specific membrane antigen (PSMA), has also demonstrated preclinical proof-of-concept. We expect to initiate a Phase I/IIa trial in metastatic castration-resistant prostate cancer in the second half of 2021.
In addition to our two named lead programs, we are advancing a portfolio of early-stage programs.
In May 2020, we entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the discovery and development of novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. We received an upfront payment, and are eligible to receive potential development and commercial milestone payments and future tiered royalties.